… in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10) ARVO 2021 … treated eye in a Ph1b/2 extension trial in CEP290 mediated Leber Congenital Amaurosis type 10. Author(s) Stephen R. …
… (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X … Russell SR, Drack AV, et al. In a phase 1b/2 trial, 11 Leber congenital amaurosis 10 (LCA10) patients received …
… of her department, aimed at developing a novel drug for Leber congenital amaurosis 10 (LCA10) patients, has … for our quest for treatments. Our lead program is for Leber congenital amaurosis (LCA), a rare genetic eye disease …
… – LCA10 and sepofarsen ProQR Expert Perspectives Series on Leber congenital amaurosis 10 and sepofarsen with Aniz Girach … 07/20/2020 - 18:00 ProQR Expert Perspectives Series on Leber congenital amaurosis 10 and sepofarsen with Aniz Girach …
ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
… Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 LEIDEN, Netherlands & … with sepofarsen in a clinical trial for CEP290 mediated Leber congenital amaurosis 10 (LCA10). “We are excited to …
